Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Significant Decrease in Short Interest

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) saw a large decline in short interest in December. As of December 31st, there was short interest totaling 80,620 shares, a decline of 17.9% from the December 15th total of 98,252 shares. Approximately 4.3% of the company’s shares are sold short. Based on an average trading volume of 54,964 shares, the days-to-cover ratio is presently 1.5 days. Based on an average trading volume of 54,964 shares, the days-to-cover ratio is presently 1.5 days. Approximately 4.3% of the company’s shares are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Acurx Pharmaceuticals stock. Armistice Capital LLC bought a new position in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned approximately 70.13% of Acurx Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on ACXP shares. HC Wainwright reissued a “buy” rating and set a $31.00 price target on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 30th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, December 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Stock Performance

ACXP stock opened at $2.65 on Monday. The company’s 50 day moving average price is $3.59 and its 200 day moving average price is $5.13. The firm has a market capitalization of $6.23 million, a price-to-earnings ratio of -0.31 and a beta of -1.22. Acurx Pharmaceuticals has a fifty-two week low of $2.44 and a fifty-two week high of $21.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.23) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.38. Equities analysts forecast that Acurx Pharmaceuticals will post -0.89 EPS for the current fiscal year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).